Skip to main content

Advertisement

Log in

Prevalence and risk factors of high echocardiographic probability of pulmonary hypertension in myeloproliferative neoplasms patients

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Pulmonary hypertension (PH) is emerging as a complication of myeloproliferative neoplasms (MPNs). This was a prospective study conducted at Chiang Mai University Hospital. The primary objective was to determine the prevalence of high echocardiographic probability of PH in MPNs patients. The secondary objectives were to determine risk factors of PH and the correlation between risk factors and peak tricuspid regurgitation velocity (TRVmax). All MPNs patients aged over 18 years, including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), were enrolled. All eligible patients underwent echocardiography for evaluation of the probability of PH in line with the 2015 European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Guidelines. Sixty-six patients with a median age of 59 years were enrolled. There were 35 PV, 25 ET, and 6 PMF patients included. The prevalence of high echocardiographic probability of PH was 4.55% (2 ET and 1 PMF). Risk factors associated with high echocardiographic probability of PHT were not analyzed. There were three risk factors associated with increased TRVmax, specifically lower hemoglobin, older age, and the presence of JAK2V617F mutation. The prevalence of high echocardiographic probability of PH in MPNs patients was 4.55%.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67–119.

    Article  Google Scholar 

  2. Simonneau G, Gatzoulis M, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D34–41.

    Article  Google Scholar 

  3. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.

    Article  CAS  Google Scholar 

  4. Yaylali YT, Yilmaz S, Akgun-Cagliyan G, Kilic O, Kaya E, Senol H, et al. Association of disease subtype and duration with echocardiographic evidence of pulmonary hypertension in myeloproliferative neoplasm. Med Princ Pract. 2020. (Epub ahead of print)

  5. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53:1573–619.

    Article  Google Scholar 

  6. Dingli D, Utz JP, Krowka MJ, Oberg AL, Tefferi A. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest. 2001;120:801–8.

    Article  CAS  Google Scholar 

  7. Gupta R, Perumandla S, Patsiornik Y, Niranjan S, Ohri A. Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders. J Natl Med. 2006;98:1779–822.

    Google Scholar 

  8. Garypidou V, Vakalopoulou S, Dimitriadis D, Tziomalos K, Sfikas G, Perifanis V. Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders. Haematologica. 2004;89:245–7.

    PubMed  Google Scholar 

  9. Lopez-Mattei J, Verstovsek S, Fellman B, Iliescu C, Bhatti K, Hassan SA, et al. Prevalence of pulmonary hypertension in myelofibrosis. Ann Hematol. 2019;99:781–9.

    Article  Google Scholar 

  10. Austin M, Quesenberry PJ, Ventetuolo CE, Liang O, Reagan JL. Prevalence and effect on survival of pulmonary hypertension in myelofibrosis. Clin Lymphoma Myeloma Leuk. 2019;19:593–7.

    Article  Google Scholar 

  11. Venton G, Turcanu M, Colle J, Thuny F, Chebrek S, Farnault L, et al. Pulmonary hypertension in patients with myeloproliferative neoplasms: a large cohort of 183 patients. Eur J Intern Med. 2019;68:71–5.

    Article  Google Scholar 

  12. Brabrand M, Hansen K, Laursen C, Larsen TS, Vestergaard H, Abildgaard N. Frequency and etiology of pulmonary hypertension in patients with myeloproliferative neoplasm. Eur J Haematol. 2019;102:227–34.

    Article  Google Scholar 

  13. Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome—negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057–69.

    Article  Google Scholar 

  14. Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120:5128–33.

    Article  CAS  Google Scholar 

  15. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895–901.

    Article  CAS  Google Scholar 

  16. Passamonti F, Cervantes F, Maria A, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115:1703–8.

    Article  CAS  Google Scholar 

  17. Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113:4829–923.

    Article  CAS  Google Scholar 

  18. Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, et al. Revised response criteria for myelofibrosis: International Working Group–Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122:1395–8.

    Article  CAS  Google Scholar 

  19. Adir Y, Elia D, Harari S. Pulmonary hypertension in patients with chronic myeloproliferative disorders. Eur Respir Rev. 2015;24:400–10.

    Article  Google Scholar 

  20. Garcia-Manero G, Schuster SJ, Patrick H, Martinez J. Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases. Am J Hematol. 1999;60:130–5.

    Article  CAS  Google Scholar 

  21. Cortelezzi A, Gritti G, Del Papa N, Pasquini MC, Calori R, Gianelli U, et al. Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status. Leukemia. 2008;22:646–9.

    Article  CAS  Google Scholar 

  22. Altintas A, Karahan Z, Pasa S, Cil T, Boyraz T, Iltumur K, et al. Pulmonary hypertension in patients with essential thrombocytopenia and reactive thrombocytosis. Leuk Lymphoma. 2007;48:1981–7.

    Article  Google Scholar 

  23. Chebrek S, Aissi K, Frances Y, Mercier C, Farnault L, Sébahoun G, et al. Pulmonary hypertension in patients with chronic myeloproliferative neoplasms. Leuk Lymphoma. 2014;55:223–5.

    Article  Google Scholar 

  24. Mattar M, Morad M, Husseiny N, Ali NH, El Demerdash DM. Correlation between JAK2 allele burden and pulmonary arterial hypertension and hematological parameters in Philadephia negative JAK2 positive myeloproliferative neoplasms: an Egyptian experience. Ann Hematol. 2016;95:1611–6.

    Article  CAS  Google Scholar 

  25. Fraidenburg D, Machado R. Pulmonary hypertension associated with thalassemia syndromes. Ann NY Acad Sci. 2016;1368:127–39.

    Article  CAS  Google Scholar 

  26. Derchi G, Galanello R, Bina P, Cappellini MD, Piga A, Lai ME, et al. Prevalence and risk factors for pulmonary arterial hypertension in a large group of β-thalassemia patients using right heart catheterization: a Webthal study. Circulation. 2014;129:338–45.

    Article  CAS  Google Scholar 

  27. Moreira EM, Gall H, Leening MJG, Lahousse L, Loth DW, Krijthe BP, et al. Prevalence of pulmonary hypertension in the general population: the Rotterdam study. PLoS ONE. 2015;10:e0130072.

    Article  Google Scholar 

  28. Berra G, Noble S, Soccal P, Beghetti M, Lador F. Pulmonary hypertension in the elderly: a different disease? Breathe. 2016;12:43–9.

    Article  Google Scholar 

  29. Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica. 2007;92:135–6.

    Article  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Ms. Antika Wongthani for assistance with the statistics in this study.

Author information

Authors and Affiliations

Authors

Contributions

YJ and ER were responsible for design of the study, data collection, interpretation of the data, and writing the manuscript. AP and LY performed the echocardiography and determined the probability of pulmonary hypertension. YJ, ER, CC, and PP analyzed the data. All authors contributed to the revision of manuscript and approved the final version.

Corresponding author

Correspondence to Ekarat Rattarittamrong.

Ethics declarations

Conflict of interest

All of the authors declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 16 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jindamai, Y., Rattarittamrong, E., Phrommintikul, A. et al. Prevalence and risk factors of high echocardiographic probability of pulmonary hypertension in myeloproliferative neoplasms patients. Int J Hematol 112, 631–639 (2020). https://doi.org/10.1007/s12185-020-02952-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-020-02952-4

Keywords

Navigation